MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Repligen Company Profile (NASDAQ:RGEN)

Consensus Ratings for Repligen (NASDAQ:RGEN) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $28.00 (19.35% upside)

Analysts' Ratings History for Repligen (NASDAQ:RGEN)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Jefferies GroupReiterated RatingHold$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Craig HallumInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Repligen (NASDAQ:RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Repligen (NASDAQ:RGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.10$0.10$0.10
Q2 20161$0.12$0.12$0.12
Q3 20161$0.11$0.11$0.11
Q4 20161$0.12$0.12$0.12
(Data provided by Zacks Investment Research)
Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Repligen (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Repligen (NASDAQ:RGEN)
DateHeadline
06/24/16 06:12 PMRegeneron Pharmaceuticals, Inc. versus Repligen Corporation Head to Head Compare - CML News
06/22/16 06:05 PMNew Broker Ratings For Repligen Corporation (NASDAQ:RGEN) - FTSE News
06/22/16 10:51 AMRepligen Corporation Stock Momentum Hits Extreme Weakness - CML News
06/22/16 10:51 AMRepligen Corporation (RGEN) Jumps 6.19% on June 20 - Equities.com
06/22/16 10:51 AMHot News: Repligen Corporation (NASDAQ:RGEN), 3M Company (NYSE:MMM), Bristol-Myers Squibb Company ... - KC Register
06/09/16 06:34 PMRepligen Corporation (NASDAQ:RGEN) Fundamental Star Rating Report - CML News
06/06/16 06:03 PMREPLIGEN CORPORATION (NASDAQ:RGEN) Financial Condition Compared to S&P 500 - CML News
06/02/16 06:34 PMBuy, Sell Or Hold Rating For Repligen Corporation (NASDAQ:RGEN)? - Share Trading News - Buy, Sell Or Hold Rating For Repligen Corporation (NASDAQ:RGEN)?Share Trading NewsRepligen Corporation has a 50 day moving average of 26.22 and a 200 day moving average of 26.05. The stock's market capitalization is 812.69M, it has a 52-week low of 20.07 and a 52-week high of 42.48. The share price of the company (NASDAQ:RGEN) ...
06/02/16 09:07 AMRepligen to Present at Jefferies 2016 Healthcare Conference - GlobeNewswire (press release) - Repligen to Present at Jefferies 2016 Healthcare ConferenceGlobeNewswire (press release)WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief ...and more »
06/02/16 06:55 AMRepligen to Present at Jefferies 2016 Healthcare Conference - [at noodls] - WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today ...
06/01/16 06:40 PMRepligen Corporation (NASDAQ:RGEN) Set To Release Quarterly Earnings - Investor Newswire - Repligen Corporation (NASDAQ:RGEN) Set To Release Quarterly EarningsInvestor NewswireAccording to a group of market experts surveyed by Zacks Research, Repligen Corporation (NASDAQ:RGEN) is projected to report earnings of $0.15 for its recent quarter. The company plans to release its quarterly report on or around 2016-08-04. It should ...and more »
05/30/16 04:55 PMNext Weeks Broker Price Targets For Repligen Corporation (NASDAQ:RGEN) - Share Trading News - Next Weeks Broker Price Targets For Repligen Corporation (NASDAQ:RGEN)Share Trading NewsRepligen Corporation has a 50 day moving average of 26.52 and a 200 day moving average of 26.10. The stock's market capitalization is 815.39M, it has a 52-week low of 20.07 and a 52-week high of 42.48. The share price of the company (NASDAQ:RGEN) ...Repligen Corporation (NASDAQ:RGEN) Short Interest Increased By 0.14%HNNRepligen Corporation (NASDAQ:RGEN) Quarterly EPS From Continuing Operations Stands At $0.0492Equities Focusall 6 news articles »
05/30/16 08:06 AMStock Rating Review for Repligen Corporation (NASDAQ:RGEN) - HNN - Stock Rating Review for Repligen Corporation (NASDAQ:RGEN)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.5 on shares of Repligen Corporation (NASDAQ:RGEN). Covering analysts ...and more »
05/29/16 09:49 PMRepligen Corporation (NASDAQ:RGEN) Short Interest Increased By 0.14% - HNN - Repligen Corporation (NASDAQ:RGEN) Short Interest Increased By 0.14%HNNThe stock of Repligen Corporation (NASDAQ:RGEN) registered an increase of 0.14% in short interest. RGEN's total short interest was 2.10 million shares in May as published by FINRA. Its up 0.14% from 2.09M shares, reported previously. With 254,400 ...and more »
05/27/16 05:11 PMRepligen : to Participate in 13th Annual Craig-Hallum Institutional Investor Conference - (GlobeNewswire) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value ... 05/26 Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Co.. 05/24 REPLIGEN CORP: Entry into a Material Definitive Agreement ...
05/26/16 04:58 PMRepligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference - GlobeNewswire (press release) - Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor ConferenceGlobeNewswire (press release)WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the ...and more »
05/26/16 02:07 PMRepligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference - [at noodls] - WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today ...
05/26/16 07:20 AM3 Stocks That Help Drugmakers Create Billion Dollar Blockbusters -
05/25/16 09:54 PMBroker Roundup For Repligen Corporation (NASDAQ:RGEN) - Share Trading News - Broker Roundup For Repligen Corporation (NASDAQ:RGEN)Share Trading News06/26/2014 – Janney Montgomery Scott began new coverage on Repligen Corporation giving the company a “buy” rating. They now have a USD 26 price target on the stock. The share price of Repligen Corporation (NASDAQ:RGEN) was up +2.64% during ...
05/24/16 10:09 PMEarnings Review and Stock Rundown for Repligen Corporation (NASDAQ:RGEN) - Wall Street Hints and News - Earnings Review and Stock Rundown for Repligen Corporation (NASDAQ:RGEN)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Repligen Corporation (NASDAQ:RGEN) to ...and more »
05/24/16 10:09 PMRepligen Corporation (RGEN) is Trading Lower on Unusual Volume for May 23 - Equities.com - Repligen Corporation (RGEN) is Trading Lower on Unusual Volume for May 23Equities.comRepligen Corporation (RGEN) experienced unusually high volume on May. 23, as the stock lost 3.63% to a closing price of $23.50. The stock saw 461,672 shares trade hands over the course of the day on 3,935 trades. Given that the stock's average daily ...
05/24/16 05:00 PMEye Catching Stocks: Repligen Corporation (NASDAQ:RGEN), Biostage, Inc. (NASDAQ:BSTG), Hugoton Royalty Trust ... - KC Register - Eye Catching Stocks: Repligen Corporation (NASDAQ:RGEN), Biostage, Inc. (NASDAQ:BSTG), Hugoton Royalty Trust ...KC RegisterRepligen Corporation (NASDAQ:RGEN) announced the pricing of an underwritten public offering of $100 million aggregate principal amount of 2.125% Convertible Senior Notes due 2021 (the “Notes”). The Company has granted the underwriters a 30-day ...Stock Rating Review for Repligen Corporation (NASDAQ:RGEN)Wall Street Hints and NewsBroker Outlook For The Week Ahead Repligen Corporation (NASDAQ:RGEN)Share Trading Newsall 11 news articles »
05/24/16 03:16 PMREPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
05/24/16 08:34 AMStock Rating Review for Repligen Corporation (NASDAQ:RGEN) - Wall Street Hints and News - Stock Rating Review for Repligen Corporation (NASDAQ:RGEN)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.5 on shares of Repligen Corporation (NASDAQ:RGEN). Covering analysts ...Broker Outlook For The Week Ahead Repligen Corporation (NASDAQ:RGEN)Share Trading NewsHot Alert: InterOil Corporation (NYSE:IOC), Fuwei Films (Holdings) Co., Ltd (NASDAQ:FFHL), Realty Income ...Benchmark Monitorall 10 news articles »
05/23/16 10:02 PMStock Paining Investors: Repligen Corporation (NASDAQ:RGEN) - Wall Street Hints and News - Stock Paining Investors: Repligen Corporation (NASDAQ:RGEN)Wall Street Hints and NewsRepligen Corporation (NASDAQ:RGEN) shares have underperformed for investors this year as the stock has dropped -40.79% for the year. Shareholders are shaking their heads and questioning their investment and pondering what their next move will be.and more »
05/22/16 04:19 PMAlpha One Assigns Impact Score Of 80 To Repligen Corporation (NASDAQ:RGEN) - Investor Newswire - Alpha One Assigns Impact Score Of 80 To Repligen Corporation (NASDAQ:RGEN)Investor NewswireAlpha One analyzed the various web articles published on Repligen Corporation (NASDAQ:RGEN), and thereafter it gave company a daily sentiment score of 0. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/21/16 04:34 PMRepligen Corporation (RGEN) Drops 8.52% on May 19 - Equities.com - Repligen Corporation (RGEN) Drops 8.52% on May 19Equities.comRepligen Corporation (RGEN) was one of the Russell 2000's biggest losers for Thursday May 19 as the stock slid 8.52% to $23.95, a loss of $-2.23 per share. Starting at an opening price of $24.77 a share, the stock traded between $23.31 and $24.77 over ...Repligen Corporation (NASDAQ:RGEN) Sellers Increased By 2.46% Their ShortsThe Postall 3 news articles »
05/20/16 03:05 PMREPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and -
05/19/16 08:45 AMBRIEF-Repligen announces pricing of $100 mln of 2.125 pct convertible senior notes due 2021 - * Repligen announces pricing of $100 million of 2.125 pct convertible senior notes due 2021 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
05/19/16 07:52 AMRepligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021 - [at noodls] - WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the 'Company') today announced the pricing of an underwritten public offering of $100 million aggregate principal amount ...
05/18/16 07:20 PMBRIEF-Repligen Corp files for mixed shelf offering - SEC filing - * Repligen Corp files for mixed shelf offering, size not disclosed Source - http://bit.ly/1WExHpA Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
05/18/16 05:35 PMBRIEF-Repligen to offer $100 mln of convertible senior notes - * Repligen announces proposed public offering of $100 million of convertible senior notes due 2021 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
05/18/16 04:54 PMShare Recap and Earnings Focus on Repligen Corporation (NASDAQ:RGEN) - Wall Street Hints and News - Share Recap and Earnings Focus on Repligen Corporation (NASDAQ:RGEN)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Repligen Corporation ...and more »
05/18/16 04:12 PMRepligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021 - [at noodls] - WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the 'Company') has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due ...
05/17/16 08:40 AMRepligen Corporation (NASDAQ:RGEN) Shorted Shares Increased By 2.46% - Wall Street Hints and News - Repligen Corporation (NASDAQ:RGEN) Shorted Shares Increased By 2.46%Wall Street Hints and NewsThe stock of Repligen Corporation (NASDAQ:RGEN) registered an increase of 2.46% in short interest. RGEN's total short interest was 2.09M shares in May as published by FINRA. Its up 2.46% from 2.04 million shares, reported previously. With 184,100 ...
05/12/16 04:18 PMREPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Secu -
05/10/16 11:48 AMRepligen Corp. :RGEN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/05/16 04:13 PMEdited Transcript of RGEN earnings conference call or presentation 5-May-16 12:30pm GMT -
05/05/16 02:37 PMRepligen tops 1Q revenue forecasts -
05/05/16 07:56 AMRepligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : May 5, 2016 -
05/05/16 07:36 AMBRIEF-Repligen Q1 EPS $0.05 - * Q1 earnings per share view $0.10 -- Thomson Reuters I/B/E/S
05/05/16 06:51 AMRepligen Reports First Quarter 2016 Financial Results - [at noodls] - WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the first ...
05/05/16 06:50 AMREPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/05/16 06:07 AMQ1 2016 Repligen Corp Earnings Release - Before Market Open -
04/29/16 03:51 PMREPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers -
04/29/16 10:47 AMRepligen to Report First Quarter 2016 Financial Results - [at noodls] - WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 financial results on Thursday, May 5, 2016. The Company ...
04/29/16 07:56 AMThe Biggest Threat to Repligen Stock - The bioprocessing leader's business looks solid, but here's one major risk for Repligen.
04/13/16 05:26 PMAnalysts Set $35.75 Target Price for Repligen Co. (NASDAQ:RGEN) - Washington News Wire - Washington News WireAnalysts Set $35.75 Target Price for Repligen Co. (NASDAQ:RGEN)Washington News WireRepligen logo Repligen Co. (NASDAQ:RGEN) has earned a consensus broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and ...and more »
04/09/16 04:47 PMRepligen Co. (RGEN) Expected to Earn FY2017 Earnings of $0.62 Per Share - Washington News Wire - Washington News WireRepligen Co. (RGEN) Expected to Earn FY2017 Earnings of $0.62 Per ShareWashington News WireRepligen logo Repligen Co. (NASDAQ:RGEN) – Research analysts at Jefferies Group issued their FY2017 earnings estimates for shares of Repligen in a research note issued on Monday, according to Zacks Investment Research. Jefferies Group analyst B.Repligen Co. (RGEN) Upgraded by Zacks Investment Research to HoldThe Vista VoiceRepligen Co. (RGEN) Rating Increased to Hold at Zacks Investment ResearchWeb Breaking NewsReviewing Share Performance for : Repligen Corporation (NASDAQ:RGEN)WallStreet.orgBusiness Standard Tribune -Vanguard Tribune -Equities.comall 11 news articles »
04/06/16 07:47 AMRepligen (RGEN) Acquires Germany-Based Atoll GmBH in Cash and Stock Deal - Repligen Corporation (NASDAQ: RGEN) announced that it has acquired Atoll GmBH (“Atoll ... Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares1 of Repligen common stock ...
About Repligen

Repligen logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Company has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGEN
  • CUSIP: 75991610
Key Metrics:
  • Previous Close: $23.46
  • 50 Day Moving Average: $24.31
  • 200 Day Moving Average: $25.50
  • P/E Ratio: 97.75
  • P/E Growth: 2.03
  • Market Cap: $789.15M
  • Current Quarter EPS Consensus Estimate: $0.47 EPS
Additional Links:
Repligen (NASDAQ:RGEN) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha